NCT04094961 2026-03-05
Ixazomib + Pomalidomide + Dexamethasone In MM
Dana-Farber Cancer Institute
Phase 1/2 Active not recruiting
Dana-Farber Cancer Institute
Karyopharm Therapeutics Inc
CellCentric Ltd.
M.D. Anderson Cancer Center
Mayo Clinic
Columbia University
Therapeutic Advances in Childhood Leukemia Consortium